SecBot SecBot
8-K ·Filed May 28, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001628280-26-038630
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine governance filing with no material financial or operational implications. Monitor for any future board changes or strategic shifts, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.55
T+0 close · May 28, 2026 · via day close
Latest settled
+2.41%
T+60 · $9.78
Vs SPY
+0.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $9.55entry
  2. T+1 · 6mo ago −0.10%α −0.34% · $9.54
  3. T+5 · 6mo ago −8.17%α −8.12% · $8.77
  4. T+20 · 5mo ago +5.03%α +8.17% · $10.03
  5. T+60 · 3mo ago +2.41%α +0.67% · $9.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to a business conflict, effective May 26, 2026, with no disagreement with the company. The board reduced its size from eight to seven members and appointed Robert More as Audit Committee Chair. The filing also summarizes the 2026 Annual Meeting results, where all three Class I director nominees were elected, the advisory vote on executive compensation passed, and Ernst & Young was ratified as auditor.

Key Facts

  • Director Saira Ramasastry stepped down from the board and Audit Committee effective May 26, 2026, due to a business conflict, not due to any disagreement with the company.
  • Board size reduced from eight to seven members.
  • Robert More appointed as Audit Committee Chair.
  • At the 2026 Annual Meeting, all three Class I director nominees (Robert More, Janet Napolitano, Elliott Sigal) were elected.
  • Advisory vote on executive compensation passed with 108,453,963 votes for, 11,863,405 against, and 1,372,563 abstentions.
  • Ratification of Ernst & Young as independent auditor passed with 137,048,756 votes for, 153,836 against, and 1,164,682 abstentions.
  • 161,234,058 shares were outstanding and entitled to vote as of the March 31, 2026 record date.

Financial Impact

No financial impact from this filing.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-038630
Document: 0001628280-26-038630-index-headers.html0001628280-26-038630
Document: 0001628280-26-038630-index.html0001628280-26-038630
Document: 0001628280-26-038630.txt0001628280-26-038630

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026